NIFTY : 10,768.05 SENSEX : 36,737.69 USDINR : 75.40 GOLD : 49,162.00
Support: +91 265 2361474
  • Equity
  • Mutual Fund
  • Derivatives
  • Commodity
  • IPO
  • Other Market

Corporate News

as on 30-Jun-2020  09:23

Shilpa Medicare launches affordable drug for treatment of advance renal cell carcinoma
Shilpa Medicare launched the Indian branded generic of Axitinib, an tyrosine kinase inhibitor drug with a brand name AXISHIL.

AXISHIL is available as 1 mg & 5 mg tablets in pack of 14's tablets in onebottle.

AXISHIL is used to treat patients suffering from Advanced Renal CellCarcinoma (RCC).

This novel targeted therapy attacks cancer cells without damaging normalcells, thus causing fewer side effects. There has been a_ significantimprovement in survival rates in patients with advanced renal cancer due to advent of this novel targeted therapy.

Currently the monthly therapy cost of innovator is approximately Rs 1.66 lakh and with the launch of AXISHIL, monthly cost of treatment will be reduced drastically to Rs 14940/-. drastically to Rs. 14940/-.

Powered by Capital Market - Live News

Copyright © 2019 VSE Stock Services Limited (“VSSL”). All Rights Reserved Developed and powered by CMOTS Infotech ( ISO 9001:2015 certified )
.